This study aims to determine the prevalence of heart failure in the resident population in mainland Portugal aged 50 years or above, using a contemporary, guideline-based diagnostic approach, to optimize patient management and improve strategic healthcare decision-making
The contemporary prevalence of heart failure in Portugal is largely unknown and may differ from that reported in early studies, which were conducted in the late 1990s-early 2000s with the diagnostic techniques available at the time and did not include neither advanced echocardiographic parameters nor natriuretic peptides measurements. Thus, a large and representative study is needed to address knowledge gaps on the epidemiology, characteristics and burden of heart failure in Portugal. The study aims to determine the prevalence of global heart failure, as well as heart failure subtypes. It also aims to assess the distribution of comorbidities among patients with heart failure, as well as patients' health-related quality of life. The Investigators will conduct a population-based study with a three-stage design approach, enrolling 5616 subjects aged 50 years or above, randomly selected through multi-stage sampling, using the National Health Service as reference: PHASE 0 - Participant selection/enrollment through phone call; PHASE 1 - Screening (NT-proBNP levels determination), health-related quality of life evaluation and sociodemographic characterization; PHASE 2 - Confirmatory assessment with a 12-lead electrocardiography, comprehensive transthoracic echocardiography, extended symptoms assessment and biomarkers assessment; PHASE 3 - Heart failure with preserved ejection fraction exertion testing through a non-invasive echocardiographic diastolic stress test.
Study Type
OBSERVATIONAL
Enrollment
6,189
Research Site
Aljustrel, Portugal
Research Site
Aveiro, Portugal
Research Site
Braga, Portugal
Research Site
Castelo Branco, Portugal
Prevalence of HF among the mainland resident Portuguese population aged 50 or above.
Prevalence of HF among the mainland resident Portuguese population aged 50 or above.
Time frame: Between March 2022 and March 2023
Age- and gender-specific prevalence of HF among the Portuguese population.
Age- and gender-specific prevalence of HF among the Portuguese population.
Time frame: Between March 2022 and March 2023
Heart Failure reduced Ejection Fraction phenotype prevalence.
Heart Failure reduced Ejection Fraction phenotype prevalence.
Time frame: Between March 2022 and March 2023
Heart Failure mildly reduced Ejection Fraction phenotype prevalence
Heart Failure mildly reduced Ejection Fraction phenotype prevalence
Time frame: Between March 2022 and March 2023
Heart Failure preserved Ejection Fraction phenotype prevalence.
Heart Failure preserved Ejection Fraction phenotypes prevalence.
Time frame: Between March 2022 and March 2023
Prevalence of asymptomatic NT-proBNP elevation.
Prevalence of asymptomatic NT-proBNP elevation.
Time frame: Between March 2022 and March 2023
Prevalence of Pre-HF, as defined by the HF universal definition 2, in patients with asymptomatic NT-proBNP elevation.
Prevalence of Pre-HF, as defined by the HF universal definition 2, in patients with asymptomatic NT-proBNP elevation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Coimbra, Portugal
Research Site
Lagos, Portugal
Research Site
Lisbon, Portugal
Research Site
Porto, Portugal
Research Site
Serpa, Portugal
Research Site
Setúbal, Portugal
...and 3 more locations
Time frame: Between March 2022 and March 2023
Prevalence of comorbidities among Portuguese HF patients
Prevalence of comorbidities among Portuguese HF patients, namely: 1. CHD, 2. previous MI, 3. hypertension, 4. obesity, 5. DM, 6. VHD, 7. AF, 8. CKD, 9. COPD, 10. OSA;
Time frame: Between March 2022 and March 2023
Prevalence of comorbidities among patients with HFrEF, HFmrEF, and HFpEF phenotypes.
Prevalence of comorbidities among patients with HFrEF, HFmrEF, and HFpEF phenotypes, namely: 1. CHD, 2. previous MI, 3. hypertension, 4. obesity, 5. DM, 6. VHD, 7. AF, 8. CKD, 9. COPD, 10. OSA.
Time frame: Between March 2022 and March 2023
Health-related quality of life 5-level Euro Quality of life-5D version (EQ-5D-5L)
Health-related quality of life 5-level Euro Quality of life-5D version (EQ-5D-5L) consists of 2 pages: the descriptive system (EQ-5D) and the visual analogue scale (EQ VAS). EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; each one has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0).
Time frame: Between March 2022 and March 2023
Health-related quality of life (Kansas City Cardiomyopathy Questionnaire - KCCQ)
Health-related quality of life (Kansas City Cardiomyopathy Questionnaire - KCCQ). The predictor was the annually updated KCCQ score. The KCCQ is a validated instrument to assess health status among persons with heart failure. The self-administered questionnaire includes 23-items which quantify the importance of dyspnea, fatigue, and edema on physical, social, and emotional functions. The responses are categorized under 3 subscales (symptom burden, physical limitation and quality of life) with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The total KCCQ score represents the mean of the three subscale scores.
Time frame: Between March 2022 and March 2023
Association between health-related quality of life questionnaire (EQ-5D-5L) results and the HF phenotype.
Association between health-related quality of life questionnaire (EQ-5D-5L) results and the HF phenotype.
Time frame: Between March 2022 and March 2023
Association between health-related quality of life questionnaire (KCCQ) results and the HF phenotype.
Association between health-related quality of life questionnaire (KCCQ) results and the HF phenotype.
Time frame: Between March 2022 and March 2023